EA202092034A3 - 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR CANCER TREATMENT - Google Patents

2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR CANCER TREATMENT

Info

Publication number
EA202092034A3
EA202092034A3 EA202092034A EA202092034A EA202092034A3 EA 202092034 A3 EA202092034 A3 EA 202092034A3 EA 202092034 A EA202092034 A EA 202092034A EA 202092034 A EA202092034 A EA 202092034A EA 202092034 A3 EA202092034 A3 EA 202092034A3
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
salts
useful
substituted anilino
cancer treatment
Prior art date
Application number
EA202092034A
Other languages
Russian (ru)
Other versions
EA202092034A2 (en
Inventor
Сэм Баттеруорт
Морис Реймонд Верскойл Финлей
Ричард Эндрью Уорд
Васанта Кришна Кадамбар
Чандрасехара Редди Чинтакунтла
Андиаппан Муруган
Хизер Мэри Редферн
Клаудио Эдмундо Чуакуи
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA202092034A2 publication Critical patent/EA202092034A2/en
Publication of EA202092034A3 publication Critical patent/EA202092034A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Настоящее изобретение относится к некоторым 2-(2,4,5-замещенным анилино)пиримидиновым соединениям и их фармацевтически приемлемым солям, которые могут быть полезны в лечении или предупреждении заболевания или медицинского состояния, опосредованного некоторыми мутированными формами рецептора эпидермального фактора роста (например, L858R активирующий мутант, активирующий мутант с делецией в экзоне 19 и T790M резистентный мутант). Такие соединения и их соли могут быть полезны в лечении или предупреждении ряда различных злокачественных новообразований. Изобретение также относится к фармацевтическим композициям, содержащим указанные соединения и их соли, особенно полезным полиморфным формам этих соединений и солей, промежуточным соединениям, полезным в получении указанных соединений, и к способам лечения заболеваний, опосредованных разнообразными различными формами EGFR, с использованием указанных соединений и их солей.The present invention relates to certain 2- (2,4,5-substituted anilino) pyrimidine compounds and pharmaceutically acceptable salts thereof, which may be useful in the treatment or prevention of a disease or medical condition mediated by certain mutated forms of epidermal growth factor receptor (e.g. L858R activating mutant, activating exon 19 deletion mutant and T790M resistant mutant). Such compounds and their salts can be useful in the treatment or prevention of a variety of different cancers. The invention also relates to pharmaceutical compositions containing said compounds and their salts, particularly useful polymorphic forms of these compounds and salts, intermediates useful in the preparation of said compounds, and to methods of treating diseases mediated by various different forms of EGFR using said compounds and their salts.

EA202092034A 2012-01-27 2012-07-25 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR CANCER TREATMENT EA202092034A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261591363P 2012-01-27 2012-01-27

Publications (2)

Publication Number Publication Date
EA202092034A2 EA202092034A2 (en) 2020-12-30
EA202092034A3 true EA202092034A3 (en) 2021-02-26

Family

ID=52394772

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202092034A EA202092034A3 (en) 2012-01-27 2012-07-25 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR CANCER TREATMENT
EA201990482A EA036521B1 (en) 2012-01-27 2012-07-25 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201990482A EA036521B1 (en) 2012-01-27 2012-07-25 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer

Country Status (2)

Country Link
CU (1) CU20130149A7 (en)
EA (2) EA202092034A3 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (en) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase
MX2009000769A (en) * 2006-07-21 2009-01-28 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors.
DK2361248T3 (en) * 2008-06-27 2019-01-14 Celgene Car Llc Heteroberl compounds and uses thereof
KR101256018B1 (en) * 2009-08-20 2013-04-18 한국과학기술연구원 1,3,6-Substituted indole derivatives having inhibitory activity for protein kinase

Also Published As

Publication number Publication date
CU20130149A7 (en) 2014-04-24
EA201990482A1 (en) 2019-07-31
EA202092034A2 (en) 2020-12-30
EA036521B1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
EA201690328A1 (en) Derivatives of 2- (2,4,5-substituted-anilino) pyrimidine as modulators of EGFR, useful for the treatment of cancer
EA201991399A1 (en) AMINOTRIAZOLOPYRIDINE COMPOUNDS AND THEIR APPLICATION IN TREATMENT OF CANCER
CY1120258T1 (en) Heterocyclic-Substituted Compounds- [1,2,4] Triazolo [1,5-C] Quinazoline-5-Amine Suitable for the Treatment or Prevention of Intermittent Disorders
EA201590345A1 (en) METHODS OF CANCER TREATMENT USING 3- (4 - ((4- (MORFOLINOMETHYL) BENZYL) OXY) -1-OXIOIZINDOLIN-2-IL) PIPERIDIN-2,6-DIONA
EA201291220A1 (en) AMINOPYRIMIDINE DERIVATIVES AS MODULATORS LRRK2
MA38380A1 (en) Quinazoline inhibitors of activation of mutant forms of epidermal growth receptor (EGFR)
EA201370166A1 (en) CONTAINING DIRYLACETHYLENEHYDRAZIDE THYROZINKINASE INHIBITORS
EA201500298A1 (en) ALCOXYPHAZOLES AS ACTIVATORS OF SOLUBLE GUANYLATZYCLASES
EA201692095A1 (en) IMIDAZO [4,5-C] QUINOLIN-2-NEW COMPOUNDS AND THEIR APPLICATION IN CANCER TREATMENT
ATE517882T1 (en) QUINOLINE DERIVATIVES
MX2010007683A (en) Fused heterocyclic derivatives and methods of use.
MX2012013206A (en) Fused bicyclic kinase inhibitors.
MX2009000531A (en) Fused heterocyclic derivatives and methods of use.
MX2013008431A (en) Mineralocorticoid receptor antagonists.
BR112014001908A2 (en) substituted heterocyclic aza derivatives
EA201692260A1 (en) 1,3,4-TIADIAZOLE COMPOUNDS AND THEIR APPLICATION IN CANCER TREATMENT
PH12020550228A1 (en) Epidermal growth factor receptor inhibitors
EA201790253A1 (en) ALDOSTERONSYNTASE INHIBITORS
MX2014003455A (en) Aryl or n-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands.
EA202092034A3 (en) 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR CANCER TREATMENT
UA106710C2 (en) COMPOUND 2- (2,4,5-substituted ANILINO) PIRIMIDINE AND ITS APPLICATION FOR CANCER TREATMENT
TH149236B (en) 2- (2,4,5- replaces -anilino) pyrimidine derivatives, an EGFR regulator, are useful in the treatment of cancer.
NZ621471A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof